Process for the preparation of eribulin mesylate intermediate
AssigneeRk Pharma Inc.
InventorsRavishanker Kovi, Jayaraman Kannappan, Shivnath Sahebrao Patil
Life of this patent
Estimating the term…
Abstract
The present application provides improved processes for the synthesis of eribulin intermediate, which generally comprise the steps of: a) De-protecting the eribulin-enone (compound 1) in tetrahydrofuran by using TBAF solution, buffered with imidazole HCl in the presence of molecular sieve and sodium sulphate to get an insitu mixture of eribulin-dione diastereomer at C12 carbon (compound 2). Then ketalization may be performed of eribulin-dione insitu intermediate containing mixture of diastereomer at C12 carbon (compound 2) with PPTS in dichloromethane to yield eribulin-diol (compound 3).
Claims1
A process for producing eribulin-diol consisting of:
- de-protecting eribulin-enone (compound 1) using 20 eq. of a TBAF solution,
- buffering the deprotected eribulin-enone (compound 1) using 10 eq. imidazole HCl in the presence of a mixture of anhydrous molecular sieves and sodium sulphate which is preheated at 110-120° C. for at least 30 minutes,
- further cooling the de-protected eribulin-enone (compound 1) to 0-5° C.,
- charging the cooled de-protected eribulin-enone (compound 1) with a solution containing imidazole hydrochloride in the TBAF solution and stirring for 24 hours between 10-20° C.,
- further filtering and distilling the residue with the addition of methanol and water in the ratio of about 9:1 therewith producing an in situ mixture of eribulin-dione diastereomer at C12 carbon (compound 2);
- and
- performing ketalization of the in situ mixture of eribulin-dione diastereomer at C12 carbon, therewith producing 70% pure eribulin-diol (compound 3).
Dependencies are inferred from the claim text.